Medico Remedies Ltd, a WHO-GMP certified pharmaceutical formulations manufacturer, has informed stock exchanges about receiving Show of Cause (SoP) notices from both NSE and BSE for alleged non-compliance with SEBI listing regulations. The company disclosed this development under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Action Details

The pharmaceutical company received SoP notices on 20th February 2026 from both major stock exchanges regarding alleged violations of Regulation 6(1) of the SEBI Listing Regulations. The regulatory action stems from compliance issues identified by the exchanges during their review processes.

Financial Implications

Both exchanges have imposed identical penalties on Medico Remedies Ltd for the alleged regulatory violations. The financial impact of the regulatory action includes specific penalty amounts from each exchange.

Company Response and Actions

Medico Remedies Ltd has taken prompt action in response to the SoP notices received from both exchanges. The company filed waiver applications with NSE and BSE on 24th February 2026, seeking relief from the imposed penalties.

The company has assessed the impact of this regulatory action on its operations and has stated that there is no material impact on its financials, operations, or other activities. This disclosure was made in compliance with SEBI's Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

About the Company

Medico Remedies Ltd is a pharmaceutical formulations manufacturer with WHO-GMP certification, ISO 9001-2015 certification, and recognition as a government-approved Star Export House. The company is headquartered in Mumbai and operates in the pharmaceutical manufacturing sector, focusing on tablet and capsule formulations.

Medico Remedies Limited has announced a key leadership appointment, naming Ms. Vidhi Ankit Shah as the company's new Company Secretary and Compliance Officer. The appointment, effective February 18, 2026, was approved by the Board of Directors during their meeting held on the same date.

Board Meeting Outcome and Clarification

The Board of Directors of Medico Remedies Limited convened on February 18, 2026, to consider and approve the appointment of Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer. Following the initial announcement, the company has provided additional clarification regarding the Board Meeting proceedings.

The company confirmed that the outcome of the Board Meeting was submitted at 4:19:04 PM, which falls within the prescribed time limits as per SEBI (LODR) Regulations 2025. This clarification was provided to BSE Limited on February 24, 2026, under acknowledgment number 12202677.

Appointee Profile and Experience

Ms. Vidhi Ankit Shah brings substantial expertise to her new role at Medico Remedies Limited. She is an associate member of the Institute of Company Secretaries of India and possesses over 9 years of experience in managing secretarial compliances for both listed and unlisted companies. Her extensive background in corporate governance and regulatory compliance positions her well to handle the responsibilities of her new position.

Appointment Details

Regulatory Compliance

The appointment has been made in accordance with Section 203 of the Companies Act, 2013, and Regulation 6 of the Listing Regulations. The company has fulfilled all necessary regulatory disclosure requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ms. Shah has formally provided her consent to act as Company Secretary and Compliance Officer, with terms and conditions to be mutually agreed upon according to the Companies Act, 2013 and Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Company Background

Medico Remedies Limited operates as a WHO-GMP certified, ISO 9001-2015 certified pharmaceutical company and is recognized as a Government Star Export House. The company specializes in manufacturing pharmaceutical formulations and maintains its registered office in Mumbai. With this strategic appointment and transparent regulatory compliance, the company continues to strengthen its corporate governance framework.